Protalix Biotherapeutics (PLX)
:PLX
Top Page
Protalix
(PLX)
Select Model
Select Model
Rating:53Neutral
Price Target:
$2.00
▼(-8.68% Downside)
Action:ReiteratedDate:04/01/26
The score reflects strong near-term catalysts and improved liquidity outlook from the EU dosing approval milestone and upbeat 2026 revenue guidance, partially offset by weak financial performance (especially negative TTM cash flow), a loss-making valuation profile (negative P/E), and bearish technical signals with the stock trading below key moving averages.
Positive Factors
Partner Commercial Execution (Chiesi)
Sustained patient growth driven by Chiesi reflects durable third-party commercialization capabilities that scale market access without Protalix shouldering full commercial costs. Over 2–6 months this supports recurring revenue, market share capture in Fabry, and reduced execution risk versus solo commercialization.
Negative Factors
Negative operating cash flow / cash burn risk
Negative TTM operating and free cash flow indicate recurring cash burn that can force financing, slow programs, or compress optionality if persistent. With higher R&D spend and timing uncertainty on reimbursements, cash generation weakness is a structural risk to sustaining pipeline advancement and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Partner Commercial Execution (Chiesi)
Sustained patient growth driven by Chiesi reflects durable third-party commercialization capabilities that scale market access without Protalix shouldering full commercial costs. Over 2–6 months this supports recurring revenue, market share capture in Fabry, and reduced execution risk versus solo commercialization.
Read all positive factors
Protalix (PLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$176.45M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth35.42%
EPS GrowthN/A
CountryUS
Employees213
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding80,571,640
10 Day Avg. Volume818,865
30 Day Avg. Volume1,096,106
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit6.79
Enterprise Value/Ebitda-43.35
Forecast
1Y Price Target
$12.00Price Target Upside447.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.2
Revenue Forecast (FY)$79.20M
Protalix Business Overview & Revenue Model
Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, A...
How the Company Makes Money
Protalix generates revenue primarily from (1) sales and profit-sharing/economic participation tied to its marketed product Elelyso (taliglucerase alfa) for Gaucher disease, and (2) collaboration-related income such as milestone payments and other ...
Protalix Earnings Call Summary
Earnings Call Date:Mar 18, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial momentum (notably EU regulatory approval for a differentiated 4-week Elfabrio dosing regimen), a material $25 million milestone that meaningfully improves near-term liquidity, and active progression of pipeline assets (PRX-115 enrollment). These positive developments were balanced against higher R&D spending (up 51%), a 2025 net loss of $6.6 million versus prior-year income, increased cost of goods sold, and near-term operational and reimbursement timing risks across EU countries and uncertainty around U.S. label changes. Overall, the company appears well positioned financially and clinically going into 2026 due primarily to the milestone and partner execution, although investors should watch cash burn, R&D spending, and timing of commercial rollout.Positive Updates
European Commission Approval of Elfabrio 4-Week Dosing
European Commission approved a 2 mg/kg every 4-week dosing regimen for Elfabrio for adults stable on enzyme replacement therapy, strengthening competitive positioning in the EU and differentiating Elfabrio versus competitors.
Negative Updates
2025 Net Loss vs. Prior-Year Profit
The company recorded a net loss of $6.6 million in 2025 compared to net income of $2.9 million in 2024, reflecting a swing of $9.5 million year-over-year driven mainly by higher R&D investment.
Read all updates
Q4-2025 Updates
Positive
Negative
European Commission Approval of Elfabrio 4-Week Dosing
European Commission approved a 2 mg/kg every 4-week dosing regimen for Elfabrio for adults stable on enzyme replacement therapy, strengthening competitive positioning in the EU and differentiating Elfabrio versus competitors.
Read all positive updates
Company Guidance
Protalix’s forward-looking guidance calls for full-year 2026 total revenues of approximately $78 million to $83 million (including a $25 million regulatory milestone from Chiesi tied to the EU 2 mg/kg every‑4‑weeks approval), with revenues from Chiesi projected at $33 million to $35 million (greater than 50% growth) and Elelyso revenues roughly $20 million to $23 million; the company expects a projected cash balance of about $50 million by early April 2026 (up from $30.3 million cash as of Dec 31, 2025, before the milestone), and reiterates a shift in revenue mix toward higher‑margin Chiesi business. For context, full‑year 2025 results included $51.8 million in goods sales, $27.0 million cost of goods sold, $19.6 million R&D expense (up 51% YoY), $11.7 million SG&A, a net loss of $6.6 million (vs. $2.9 million net income in 2024), $0.1 million net financial expense, and $1.0 million income tax expense; the company also noted ongoing higher R&D investment to support PRX‑115 (Phase II RELEASE enrolling, topline expected H2 2027) and other renal programs.Protalix Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
68
Positive
Cash Flow
36
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.74M | 53.40M | 65.49M | 47.64M | 38.35M |
| Gross Profit | 25.75M | 29.08M | 42.51M | 28.05M | 22.00M |
| EBITDA | -4.04M | 6.52M | 12.94M | -10.78M | -18.94M |
| Net Income | -6.60M | 2.93M | 8.31M | -14.93M | -27.58M |
Balance Sheet | |||||
| Total Assets | 82.35M | 73.42M | 84.43M | 55.79M | 73.67M |
| Cash, Cash Equivalents and Short-Term Investments | 30.98M | 34.83M | 44.56M | 22.18M | 38.98M |
| Total Debt | 8.32M | 5.53M | 27.69M | 33.47M | 33.47M |
| Total Liabilities | 34.12M | 30.21M | 50.87M | 66.43M | 79.70M |
| Stockholders Equity | 48.23M | 43.21M | 33.57M | -10.64M | -6.04M |
Cash Flow | |||||
| Free Cash Flow | -13.63M | 7.39M | -2.47M | -25.63M | -11.74M |
| Operating Cash Flow | -11.99M | 8.67M | -1.32M | -25.00M | -10.29M |
| Investing Cash Flow | -2.37M | 4.22M | -16.71M | -5.04M | 18.92M |
| Financing Cash Flow | 9.33M | -16.79M | 24.67M | 8.24M | 12.08M |
Protalix Technical Analysis
Neutral
2.19
Price Trends
2.61
Negative
2.23
Negative
2.03
Positive
Market Momentum
-0.15
Positive
40.07
Neutral
66.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Neutral. The current price of 2.19 is below the 20-day moving average (MA) of 2.36, below the 50-day MA of 2.61, and above the 200-day MA of 2.03, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 40.07 is Neutral, neither overbought nor oversold. The STOCH value of 66.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLX.
Protalix Risk Analysis
Protalix disclosed 64 risk factors in its most recent earnings report. Protalix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protalix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $176.45M | -21.41 | -13.46% | ― | 35.42% | ― | |
52 Neutral | $250.32M | -1.00 | 789.35% | ― | -72.54% | -19972.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $809.92M | -18.84 | -63.06% | ― | ― | 59.04% | |
48 Neutral | $277.99M | -3.54 | -36.38% | ― | ― | 48.84% | |
47 Neutral | $120.93M | -1.23 | -271.32% | ― | -75.77% | -31.24% | |
45 Neutral | $363.39M | -40.48 | -110.72% | ― | ― | 77.08% |
* Healthcare Sector Average
PLX
Protalix
2.19
-0.15
-6.41%
CHRS
Coherus Biosciences
1.67
0.88
110.33%
SLS
SELLAS Life Sciences Group
4.51
3.39
302.68%
TARA
Protara Therapeutics
5.14
1.14
28.50%
FBRX
Forte Biosciences
26.17
20.47
359.12%
IPHA
Innate Pharma
1.35
-0.46
-25.62%
Protalix Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Protalix Gains EU Approval for Extended Elfabrio Dosing
Positive
Mar 9, 2026
On March 9, 2026, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Commission approved a 2 mg/kg every‑four‑weeks dosing regimen for Elfabrio (pegunigalsidase alfa) in adults with Fabry d...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing
Positive
Feb 11, 2026
On February 11, 2026, Protalix BioTherapeutics posted an updated corporate presentation outlining recent clinical and regulatory developments, most notably a positive opinion by the European Medicines Agency’s Committee for Medicinal Product...
Business Operations and StrategyProduct-Related Announcements
Protalix Wins EMA Panel Backing for New Elfabrio Dosing
Positive
Jan 30, 2026
On January 30, 2026, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Protalix outlines 2026 rare-disease growth and pipeline strategy
Positive
Jan 5, 2026
On January 5, 2026, Protalix BioTherapeutics released a letter to stockholders outlining its strategy to build a growing, profitable rare-disease business anchored by commercial partnerships and an expanding pipeline. Management highlighted solid ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.